^
Association details:
| Biomarker: | ERBB3 E952Q |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Published date:
01/21/2021
Excerpt:
The anti-proliferative effects of neratinib, lapatinib, and tucatinib were examined across a panel of 115 cancer cell lines...both cancer cell lines (SKBR3 and AU565) that were HER3E952Q mutant were highly sensitive to neratinib…
DOI:
10.1038/s41416-020-01257-x
